<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980304</url>
  </required_header>
  <id_info>
    <org_study_id>ML22515</org_study_id>
    <nct_id>NCT00980304</nct_id>
  </id_info>
  <brief_title>R Retreatment in 1st Relapsed DLBCL</brief_title>
  <official_title>A Multicenter, Open Label, Phase II Trial of Rituximab in Combination With ICE as Salvage Therapy in the Relapsed DLBCL Patients After 1st Line Induction Treatment of 6-8 Cycles of RCHOP-LIKE Chemo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <brief_summary>
    <textblock>
      It is a phase II , multicenter, open label clinical trial. Only the relapsed DLBCL patients&#xD;
      after 1st line induction treatment of 6~8 cycles of RCHOP-like chemo will be enrolled to&#xD;
      receive 3 cycles of RICE as salvage therapy.&#xD;
&#xD;
      After treatment each patient should be followed up for 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>1</number_of_arms>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>Rituximab in combination with ICE as salvage therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab in combination with ICE as salvage therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Relapsed DLBCL patients having received 6 - 8 cycles of RCHOP-like chemotherapy as 1st&#xD;
             line induction treatment.&#xD;
&#xD;
          2. Disease relapsed no earlier than 6 months after prior induction treatment.&#xD;
&#xD;
          3. Confirmed CD20 positivity of the lymphoma at time of diagnosis (prior to induction&#xD;
             therapy)&#xD;
&#xD;
          4. ECOG performance status of 0, 1 or 2 at time of inclusion (see Appendix IV )&#xD;
&#xD;
          5. Known IPI at time of diagnosis (prior to induction therapy)&#xD;
&#xD;
          6. Age ≥18 years and &lt;65 y&#xD;
&#xD;
          7. Life expectancy of &gt; 3 months&#xD;
&#xD;
          8. Be willing and able to comply with the protocol for the duration of the study&#xD;
&#xD;
          9. Agree to use effective contraception for the entire treatment period and during the 12&#xD;
             months thereafter&#xD;
&#xD;
         10. Patient's written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. More than one prior chemoimmunotherapy regimen.&#xD;
&#xD;
          2. Histologies other than DLBCL according to the WHO/REAL classification&#xD;
&#xD;
          3. History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the&#xD;
             skin, surgically treated malignant melanoma or carcinoma in situ of the cervix within&#xD;
             the last 5 years.&#xD;
&#xD;
          4. Major surgery, other than diagnostic surgery, within the last 4 weeks.&#xD;
&#xD;
          5. Evidence of CNS involvement patients&#xD;
&#xD;
          6. Unacceptable hematologic status at baseline prior to study start below any of the&#xD;
             values listed: WBC: &lt;3 x 109/L; absolute neutrophil count (segmented + bands) &lt;1.5 x&#xD;
             109/L; platelets: &lt;100 x109/L&#xD;
&#xD;
          7. Abnormal liver function tests prior to study start above any of the values listed:&#xD;
             serum bilirubin &gt;2 mg/dL (30 mmol/L); ALAT or ASAT &gt;2.5 x upper limit of normal range;&#xD;
             or Abnormal renal function (serum creatinine &gt; 150 μmol/L ).&#xD;
&#xD;
          8. HIV-positive patients.&#xD;
&#xD;
          9. Contraindication to the investigational medication&#xD;
&#xD;
         10. Active viral hepatitis, specifically HBV or HCV infection&#xD;
&#xD;
         11. Serious underlying medical conditions, (e.g. ongoing infection, uncontrolled diabetes&#xD;
             mellitus, severe cardiac dysfunction or angina, gastric ulcers, active autoimmune&#xD;
             disease)&#xD;
&#xD;
         12. Life expectancy &lt; 3 months&#xD;
&#xD;
         13. Treatment within a clinical trial within 30 days prior to trial entry&#xD;
&#xD;
         14. Women who are breast feeding, are not using effective contraception, are pregnant&#xD;
&#xD;
         15. Patients under tutelage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shen, Zhixiang / Professor</name_title>
    <organization>Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine</organization>
  </responsible_party>
  <keyword>Diffuse large B cell lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

